莎普爱思：公司拟开展去氧肾上腺素酮咯酸溶液临床试验

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new ophthalmic drug, deoxymidodrine ketorolac solution, aimed at maintaining pupil dilation during cataract surgery and alleviating postoperative eye pain [1] Group 1: Company Developments - The drug is specifically designed for use during cataract surgery or artificial lens replacement procedures [1] - The company plans to initiate clinical trials once conditions are met [1] - Cumulative research and development investment in the project has reached approximately 5.56 million RMB [1]